The FDA approved Spravato in March, but a new paper in JAMA examines some of the barriers inherent in the practice and reimbursement of psychiatry that could get in the way of widespread use of the drug.
Briefing documents from the Psychopharmacologic Drugs Advisory Committee earlier this week had cast doubt on the chances of a positive vote.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Iodine is teaming up with TMS Health Solutions, a network of psychiatric service providers in Northern California, to make Start a part of depression treatment at TMS clinics.
There seems to be a correlation between diabetes and depression, and medications to treat the latter might be effective for both.
Just weeks after being acquired by Allergan, the team behind Chicago-based Naurex is launching a new startup: Aptinyx. It'll focus on developing drugs for diseases of the brain and nervous system.
Some FDA approved drugs used for a variety of conditions could potentially be effective in treating Ebola in its early stages.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Many people suffer from depression and just take their doctor’s word for it on whether or not they should be medicated (not to mention which drug) and/or seek psychotherapy. There really hasn’t been a ton of research looking at how a doctor can or should make these decisions. With drug choice especially, it is kind […]